- Conditions
- Adult B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Chronic Disease, +31 more
- Locations
-
Not specified
Clinical trial condition
Lymphoma, Mantle-Cell
Explore clinical trials studying Lymphoma, Mantle-Cell. Study availability and eligibility vary by location and protocol.
894 public trials
110 recruiting studies
Lymphoma, Mantle-Cell trial results
Not yet recruiting
ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
NCT07264894
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
- The first affiliated hospital of Zhengzhou University Zhengzhou, Henan, China
Not yet recruiting
PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma
NCT07207785
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
- IRCCS Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" - IRST S.R.L. - Ematologia Meldola, Forlì-Cesena, Italy
- Istituto Clinico Humanitas - U.O. Ematologia Rozzano, Milano, Italy
- AOU Ospedali Riuniti - Clinica di Ematologia Ancona, Italy
- Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico Avellino, Italy
Not yet recruiting
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
NCT07206264
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
- Fujian Provincial Cancer Hospital Fuzhou, Fujian, China
- Hebei Medical University Tumor Hospital Shijiazhuang, Hebei, China
- Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
- Shandong Cancer Hospital Jinan, Shandong, China
Not yet recruiting
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
NCT07024147
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +16 more
- Locations
-
- Beijing cancer hospital Beijing, Beijing Municipality, China
NCT06656221
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
Not specified
Not yet recruiting
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT06427213
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
- Locations
-
Not specified
Not yet recruiting
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
NCT06324994
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
- The Second Hospital Dalian Medical University Dalian, Liaoning, China
Not yet recruiting
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
NCT06255704
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
- Hematology Department of ShanXi Cancer Hospital Taiyuan, Shanxi, China
Not yet recruiting
Patient Perspectives in Mantle Cell Lymphoma Clinical Research
NCT06049472
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
- Power Life Sciences San Francisco, California, United States